인도의 인슐린 펌프 시장 평가 : 유형별, 제품별, 부속품별, 적응증별, 연령대별, 최종사용자별, 유통채널별, 지역별, 기회 및 예측(2017년-2031년)

India insulin pumps market size was valued at USD 31.8 million in FY2023, which is expected to reach USD 60.63 million in FY2031, with a CAGR of 8.4% for the forecast period between FY2024 and FY2031. India insulin pumps market is being driven by factors including the rising prevalence of diabetes, increasing demand for insulin delivery devices that prioritize convenience and user-friendliness, technological advancements, government initiatives, growing elderly population, and increasing healthcare expenditure.

India insulin pumps market holds a central position in the healthcare arena and is poised for significant expansion and evolution. As prevalence of diabetes continue to rise, the need for advanced diabetes management solutions becomes more serious. In this context, the insulin pumps market in India stands as a pioneer of innovation, providing hope for individuals navigating the complexities of diabetes management for seeking enhanced methods of blood glucose regulation. These devices offer the distinct advantage of delivering precise insulin doses with minimal effort, rendering them invaluable assets in the realm of diabetes management.

Government efforts to alleviate the diabetes burden and reduce healthcare expenses are driving the expansion of India insulin pumps market. Public health initiatives and policies advocating the adoption of advanced diabetes management technologies have improved insulin pump accessibility and affordability, benefiting a wider cross-section of the Indian populace. Moreover, India's aging demographics is a key factor in the growing insulin pumps market. The elderly population, prone to diabetes, requires efficient insulin management solutions. In this context, the India insulin pumps market emerges as a source of optimism, presenting innovative and accessible choices for individuals striving to achieve improved diabetes control and ultimately enhancing their quality of life.

Heightened Awareness is Propelling Market Growth

The surging awareness of insulin pumps in India is exerting a favourable influence on the India insulin pumps market. Individuals with diabetes increasingly recognize the advantages of insulin pumps, including enhanced blood sugar management and reduced hypoglycaemia risk. This heightened awareness is driving the demand for insulin pumps, fostering market expansion. Additionally, organizations such as the Indian Diabetes Association are playing a crucial role in rising awareness about insulin pumps, dispelling associated misconceptions, and striving to enhance affordability and accessibility for individuals with diabetes. As awareness of insulin pumps continues to rise, the Indian market for these devices is anticipated to expand, creating opportunities for insulin pump developers and manufacturers.

Increasing India's Ageing Population

India insulin pumps market is experiencing a notable transformation driven by the country's aging demographics. With a swiftly expanding elderly population, India is encountering a remarkable increase in the incidence of diabetes, notably Type 2 diabetes, within this age cohort. Consequently, there has been a substantial rise in the demand for insulin pumps as a pivotal instrument for effective diabetes management. The elderly demographic's inherent vulnerability to diabetes underscores the vital necessity for precise insulin control. This demographic shift is reshaping the healthcare landscape, particularly in the context of diabetes care in India. The ageing population is at a higher risk of developing diabetes. It is due to several factors, including the decline in physical activity and the increase in obesity. The increasing prevalence of diabetes is leading to an increased demand for insulin pumps.

Government Initiatives

Government actions are instrumental in shaping the India insulin pumps market. The Indian government has introduced a range of policies, programs, and subsidies to enhance access to insulin pumps and diabetes management technologies, especially for economically challenged individuals. This essay delves into the diverse facets in India, encompassing aspects, like accessibility, affordability, and the advancement of diabetes care technology, driven by the recognition of the growing diabetes burden.

As an example, in May 2023, the state government declared its intention to furnish complimentary insulin pumps to individuals with Type-1 diabetes. Given the substantial expense associated with insulin pumps, those hailing from economically challenged backgrounds find them financially inaccessible. Consequently, in the absence of these pumps, these patients resort to daily insulin injections, which elevates their susceptibility to severe infections affecting vital organs, such as the kidneys.

Rising Demand for Integrated Insulin Pumps

The India insulin pumps market is undergoing a significant evolution due to the introduction of integrated insulin pumps. This revolutionary technology merges insulin administration with continuous glucose monitoring (CGM), promising to revolutionize diabetes management. Integrated systems have the potential to redefine the way diabetes is controlled by offering real-time glucose data and automated insulin delivery, creating a seamless and highly precise method for managing blood sugar levels. The integrated insulin pumps are experiencing heightened demand owing to their capacity to improve blood sugar regulation and lower the risk of hypoglycaemia. As competition intensifies within the market, it is anticipated that the prices of integrated insulin pumps will decrease. The cost reduction will enhance affordability, making these devices more accessible to individuals managing diabetes.

Increasing Need for Insulin Pumps in Type 1 Diabetes

The rising need for solutions in Type 1 Diabetes has substantially led to the growth of India insulin pumps market. The demand for insulin pumps to manage Type 1 diabetes has witnessed a remarkable upswing, reflecting a pivotal shift in the realm of diabetes care. As Type 1 diabetes, an autoimmune condition characterized by insufficient insulin production, continues to affect millions worldwide, the need for advanced solutions to streamline insulin delivery and enhance glycaemic control has surged. For individuals, particularly youngsters, managing Type 1 diabetes, insulin pumps present a viable alternative. These devices can provide a consistent insulin supply, offering a reliable solution for those who may find it challenging to adhere to a strict schedule for insulin injections.

As an illustration, in March 2023, Medtronic unveiled the introduction of the MiniMed 780G system in the Indian market. This system, designed for individuals aged 7 to 80 years with type 1 diabetes, operates as a closed-loop insulin pump system. It harnesses Medtronic's SmartGuard technology to automate the administration of both basal insulin and correction boluses at five-minute intervals. This innovative approach assists individuals with diabetes in navigating their blood sugar levels with increased convenience, minimizing the occurrence of high and low glucose levels.

Impact of COVID-19

The COVID-19 pandemic had a twofold effect on the India insulin pumps market. It has negatively impacted the market due to disruptions in supply chains, limited access to healthcare facilities, and led to economic uncertainties. Import restrictions have resulted in shortages of insulin pumps and diabetes care products, hampering patient access to these devices. Additionally, reduced access to healthcare facilities has posed challenges for diabetes patients in receiving necessary care, including insulin pump therapy. Certain insurance providers have scaled back or entirely removed their coverage for insulin pumps, rendering them less accessible for individuals managing diabetes. However, the pandemic has increased awareness of managing chronic conditions like diabetes, potentially driving demand for insulin pumps. To ensure patient access to essential care and devices, market stakeholders must adapt to the evolving pandemic conditions.

Key Players Landscape and Outlook

The insulin pumps market in India is currently undergoing a significant shift with the rise of new entrants who are redefining the competitive terrain. Historically dominated by well-established healthcare companies, this market is now embracing innovative newcomers who bring fresh insights and state-of-the-art solutions. These emerging players are infusing dynamism into the industry by introducing novel technologies, promoting robust competition, and, most crucially, broadening the reach and affordability of insulin pumps to a wider cross-section of the Indian population.

In the realm of insulin pumps, Indian startups are leading the charge in innovation, reshaping the diabetes management landscape. Amid the growing prevalence of diabetes, these entrepreneurial ventures are leveraging their creativity to craft inventive solutions tailored to the specific requirements of diabetes management in India. For instance, in May 2023, Open MedLabs, an Indian startup, revealed its work on "InsuFlo," an open-loop insulin pump designed to be cost-effective for type-1 diabetic patients in resource-limited settings. The device has reached the prototype phase, demonstrating clinically precise insulin delivery. An upcoming animal study is planned. Ongoing efforts aim to elevate the device's Technology Readiness Level (TRL) and minimize its size to match competitors.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of Covid-19 on India Insulin Pumps Market

4. Executive Summary

5. India Insulin Pumps Market Outlook, FY2017-FY2031

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
  • 5.1.2. By Volume
• 5.2. By Type
  • 5.2.1. Standalone Insulin Pumps
  • 5.2.2. Sensor Integrated Insulin Pumps
• 5.3. By Product
  • 5.3.1. Pumps
    • 5.3.1.1. Tethered Pumps
    • 5.3.1.2. Patch Pumps
    • 5.3.1.3. Others
  • 5.3.2. Consumables
• 5.4. By Accessories
  • 5.4.1. Insulin Reservoir or Cartridges
  • 5.4.2. Insulin Set Insertion Devices
  • 5.4.3. Battery
• 5.5. By Disease Indication
  • 5.5.1. Type 1 Diabetes
  • 5.5.2. Type 2 Diabetes
• 5.6. By Age Group
  • 5.6.1 Adult
  • 5.6.2. Paediatrics
  • 5.6.3. Both
• 5.7. By End-user
  • 5.7.1. Hospitals
  • 5.7.2. Clinics
  • 5.7.3. Homeware
  • 5.7.4. Laboratories
• 5.8. By Distribution Channel
  • 5.6.1 Retail Stores
  • 5.6.2 Hospital Pharmacy
  • 5.6.3 E-commerce
• 5.9. By Region
  • 5.9.1. North
  • 5.9.2. South
  • 5.9.3. East
  • 5.9.4. West and Central
• 5.10. By Company Market Share (%), FY2023

6. Market Mapping, FY2023

• 6.1. By Type
• 6.2. By Product
• 6.3. By Accessories
• 6.4. By Disease Indication
• 6.5. By Age Group
• 6.6. By End-user
• 6.7. By Distribution Channel
• 6.8. By Region

7. Macro Environment and Industry Structure

• 7.1. Supply Demand Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

• 10.1 Clinical Trials
• 10.2 Patent Landscape
• 10.3 Regulatory Approvals
• 10.4 Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, FY2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)
• 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. India Medtronic Pvt. Ltd.
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus & Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. Agva Healthcare Pvt. Ltd.
• 13.3. Ypsomed India Pvt. Ltd.
• 13.4. Tandem Diabetes Care, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer